SCOOP: Querétaro is the first of four clubs expected to change hands ahead of a private equity investment that would transform Liga MX—and could narrow the valuation gap with MLS.Read more about the sale: https://t.co/EoQbjnYQ8k(Photo: Agustin Cuevas via Getty Images) https://t.co/eRw2kPSkm1 ...

SCOOP: Querétaro is the first of four clubs expected to change hands ahead of a private equity investment that would transform Liga MX—and could narrow the valuation gap with MLS.Read more about the sale: https://t.co/8vdK6zPg3Y(Photo: Agustin Cuevas via Getty Images) https://t.co/aeZSqe358i ...

Core Insights - NeOnc Technologies Holdings, Inc. has signed a non-binding term sheet with Quazar Investment to establish a new investment and clinical platform in the MENA region [1][2] - The partnership aims to leverage the UAE's clinical trial infrastructure to advance NeOnc's late-stage drug candidates [3][7] Investment and Structure - The term sheet outlines the formation of NuroMENA Holdings Ltd, which will oversee the establishment of NuroCure, an Abu Dhabi-based subsidiary responsible for clinical trials [2][5] - A proposed equity investment of $50 million is contingent upon NeOnc meeting specific conditions within 120 days [4][8] Clinical Development - NuroCure will initiate clinical trials for NEO100 and NEO212, targeting aggressive brain cancers such as Diffuse Intrinsic Pontine Glioma and glioblastoma multiforme [7][9] - The partnership is positioned to enhance NeOnc's clinical programs through collaboration with Cleveland Clinic Abu Dhabi [3][10] Financial Strategy - Quazar will lead a capital formation round of up to $50 million, with 70% allocated for acquiring NeOnc common stock and 30% for clinical trial and infrastructure development [8][10] - The investment strategy includes executing a Sub-License Agreement for NEO100 and NEO212, facilitating clinical efforts in the region [5][11] Company Background - NeOnc Technologies is focused on developing therapeutics for central nervous system cancers, with a robust patent portfolio extending to 2038 [11] - The company's drug candidates, NEO100 and NEO212, are currently in Phase II clinical trials under FDA Fast-Track status [11]

LEXINGTON, Ky., July 07, 2025 (GLOBE NEWSWIRE) -- MiddleGround Capital (“MiddleGround”), an operationally focused private equity firm that makes control investments in North American and European headquartered middle-market B2B industrial and specialty distribution companies, today announced that it has entered a definitive agreement to sell its portfolio company Arrow Tru-Line (“ATL”), an independent manufacturer and supplier of structurally critical overhead garage door hardware components, to the Chamber ...

（原标题：北京新源股权投资基金完成备案 | 企查查LP周报(06.30-07.06)） 新备案私募基金数量表 企查查大数据研究院依据上周(06.30-07.06)新备案私募股权、创业投资基金信息，剔除GP及自然人后， 涉及169家LP投资方企业（去重后），将未公开认缴出资金额和认缴比例信息剔除后，累计认缴金额 380.89亿元人民币。从LP所属地区分布看，主要分布在江苏省，占比为江苏省15.38%；累计认缴金额最 高是湖南省和浙江省，占比为湖南省14.21%、浙江省12.81%。本周政府背景资金认缴金额最高，累计 307.61亿元人民币，占比80.76%。 企查查数据显示，上周(06.30-07.06)中国证券投资基金业协会（简称"中基协"）新备案私募股权、创业 投资基金共79支，累计募集认缴金额404.48亿元人民币。从基金所属地区分布看，新备案基金数量最多 是浙江省，新备案18支基金，合计占比22.78%；累计募资认缴金额最高是北京市和湖南省，占比为北 京市13.68%、湖南省13.23%。募集认缴金额较大的基金是北京新源股权投资基金，规模40亿元，该基 金由中国中信金融资产管理股份有限公司、海港人寿保险 ...

Core Viewpoint - Alaris Equity Partners Income Trust will release its financial results for the second quarter and first half of 2025 on August 7, 2025, with a conference call scheduled for August 8, 2025 to discuss the results and outlook [1]. Group 1 - Alaris Equity Partners Income Trust is focused on investing in a diversified group of private businesses primarily through structured equity [3]. - The primary goal of Alaris's structured equity investments is to deliver stable and predictable returns to unitholders through cash distributions and capital appreciation [3]. - The investment strategy is enhanced by common equity positions, aligning returns with the founders of Private Company Partners [3]. Group 2 - Participants interested in the conference call must register in advance to receive dial-in numbers and a unique PIN [2]. - A replay of the conference call will be available two hours after the event and archived for six months [2]. - Additional information can be found on Alaris's website under the "Investors" section [2].

Core Viewpoint - Apollo has agreed to sell its interest in MAFTEC Group Co., Ltd., a leader in ultra-high temperature heat insulating solutions, to funds managed by Advantage Partners, with the transaction expected to close in the second half of 2025 [1][5]. Company Overview - MAFTEC was established from the separation of Mitsubishi Chemical's Thermal and Emission Control Materials business, which Apollo acquired in March 2022 [2]. - Apollo played a crucial role in MAFTEC's product development and market establishment, contributing to significant EBITDA growth over the past three years [2][3]. Management Insights - Tetsuji Okamoto from Apollo expressed pride in MAFTEC's achievements and confidence in its long-term growth potential, highlighting the company's innovative material processing technology [3]. - Kosuke Matsuzaki, CEO of MAFTEC, acknowledged Apollo's support in executing the company's standalone strategy and expressed optimism about future collaboration with Advantage Partners [4]. Investment Strategy - The investment in MAFTEC reflects Apollo's strategy as a solution provider and strategic partner to leading Japanese conglomerates, with previous investments including Panasonic Automotive Systems and Altemira [4].

Goldman Sachs Alternatives served as lead investor; additional investments from BlackRock Secondaries & Liquidity SolutionsNEW YORK, June 24, 2025 /PRNewswire/ -- Avista Healthcare Partners ("Avista"), a leading private equity firm focused exclusively on healthcare, today announced the successful close of Avista Healthcare Partners CV II, L.P., a single-asset continuation fund for GCM, a leading outsourced manufacturer of complex precision components for high-growth medical technology end markets. The conti ...

ICG Enterprise Trust plc NAV per Share of 2,011p; LTM NAV per Share Total Return of 6.3% (5 year annualised: 14.8%) Q1 Portfolio Return on a Local Currency Basis of 0.6%, offset by FX, resulting in Portfolio Return on a Sterling Basis of (2.4)% and NAV per Share Total Return of (2.6)% Total Proceeds of £149m, including £62m net proceeds from the sale of a portion of our Portfolio at a 5.5% discount and £48m from sale of Minimax (previously our largest portfolio company holding); Total New Investments of £48 ...

ab Global Research 19 June 2025 Global Equity Strategy The dollar: why the bear market continues and UBS forecasts the dollar to continue to weaken to EUR/USD1.23-year end and YEN/ USD130 year-end. Of the major currencies, only the RMB and the Mexican Peso are forecast by UBS to depreciate beyond their forward rate against the dollar by year-end. Tactically, the dollar can continue to weaken despite DXY being close to a three- year low: UBS forecasts US GDP growth to slow from 1.7% YoY in Q2 to 0.9% Q4 YoY ...